<DOC>
	<DOCNO>NCT02230306</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness combination vemurafenib cobimetinib patient active melanoma brain metastasis .</brief_summary>
	<brief_title>Phase II Study Cobimetinib Combination With Vemurafenib Active Melanoma Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Signed informed consent Histologically confirm metastatic melanoma ( Stage IV ) , carry BRAF V600mutation Melanoma must document contain BRAFV600 mutation CLIA approve laboratory At least one measurable intracranial target lesion follow criterion meet : 1. previously untreated progressive accord RECIST 1.1 ( equal great 20 % increase long diameter baseline scan ) previous local therapy ( SRS and/or craniotomy ) 2. immediate local therapy clinically indicate patient suitable candidate receive immediate local therapy ( SRS and/or craniotomy ) 3. large diameter ≥ 0.5cm ≤ 4 cm determine contrastenhanced MRI Prior therapy extracranial metastatic melanoma include chemo , cytokine , immuno , biological vaccinetherapy allow prior BRAF MEK allow ECOG PS 02 Life expectancy &gt; 12 week Age 18 year old Adequate bone marrow function indicate follow : 1 . ANC &gt; 1500/µL 2 . Platelets ≥ 100,000/µL 3 . Hemoglobin &gt; 9 g/dL Adequate renal function , indicate creatinine =/ &lt; 1.5 x upper limit normal ( ULN ) Adequate liver function , indicate bilirubin =/ &lt; 1.5 x ULN AST ALT &lt; 3 x ULN ( patient document liver metastasis : AST and/or ALT =/ &lt; 5 x ULN ) Able swallow pill Negative serum pregnancy test within 7 day prior commencement dose premenopausal woman . Women nonchildbearing potential may include without serum pregnancy test either surgically sterile postmenopausal ≥ 1 year Fertile men woman must use effective method contraception treatment least 6 month completion treatment direct physician . Effective method contraception define result low failure rate ( i.e. , less 1 % per year ) use consistently correctly ( example implant , injectables , combine oral contraception intrauterine device ) . At discretion Investigator , acceptable method contraception may include total abstinence case lifestyle patient ensures compliance . ( Periodic abstinence [ e.g. , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception . ) Active infection Prior therapy BRAFi and/or MEKi Leptomeningeal disease Symptomatic brain metastasis require immediate local intervention craniotomy SRS Increasing corticosteroid dose 7 day prior administration first dose study drug . Symptomatic patient stable decrease corticosteroid use past 7 day allow Current use therapeutic warfarin Unresolved toxicity National Cancer Institute Common Terminology Criteria Adverse Events , version 4.0 ( NCI v4.0 ) [ NCI , 2009 ] Grade 2 high previous anticancer therapy , except alopecia Conditions interfere significantly absorption drug Inability undergo MRI secondary metal , claustrophobia , Gadolinium Contrast allergy Pregnant , lactating , breast feeding woman Prior radiation therapy within last 14 day Concomitant malignancy previous malignancy within last 5 year , exception adequately treat basal squamous cell carcinoma skin carcinoma situ cervix Unwillingness inability comply study followup procedures The following foods/supplements prohibit least 7 day prior initiation study treatment : 1 . St. John 's wort hyperforin 2 . Grapefruit juice History evidence retinal pathology ophthalmologic examination consider risk factor neurosensory retinal detachment , Retinal Vein Occlusion ( RVO ) , neovascular macular degeneration Uncontrolled glaucoma intraocular pressure &gt; 21mmHg Serum cholesterol ≥ Grade 2 Hypertriglyceridemia ≥ Grade 2 Hyperglycemia ( fast ) ≥ Grade 2 History clinically significant cardiac dysfunction , include follow : 1 . Current unstable angina 2 . Current symptomatic congestive heart failure NYHA class 2 high 3 . History congenital long QT syndrome mean QTcF &gt; 450 msec baseline uncorrectable electrolyte abnormality 4 . Uncontrolled hypertension ≥ Grade 2 ( patient history hypertension control antihypertensive ≤ Grade 1 eligible ) 5 . Left ventricular ejection fraction ( LVEF ) 50 % 6 . Uncontrolled Arrhythmias 7 . Myocardial infarction , severe/unstable angina , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack within previous 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>